^
Association details:
| Biomarker: | PIK3CA exon 20 mutation + HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
Excerpt:
We demonstrated that the recurrent tumor was HR negative and HER2 positive, had a PIK3CA mutation in exon 20, and expressed PTEN as shown by IHC….The response improved with increased everolimus dosage, and the tumor size slightly increased with dosage reduction. These findings suggest the existence of a dose–effect relationship.
DOI:
10.2147/OTT.S104398
